在欧洲，使用elexaftor /tezacaftor/ivacaftor的囊性纤维化跨膜电导调节疗法减少了标志性囊性纤维化病原体的检测：取得了进展，但没有时间放慢速度。

IF 4 3区医学 Q1 RESPIRATORY SYSTEM

ERJ Open Research Pub Date : 2025-08-04 eCollection Date: 2025-07-01 DOI:10.1183/23120541.00211-2025

Katharina Schütz, Sophia T Pallenberg, Ilona Rosenboom, Anna-Maria Dittrich

引用次数: 0

摘要

ETI降低了呼吸样本中的病原体检出率，但相当大比例的pwCF继续携带标志性病原体，使他们面临肺功能更快下降的风险https://bit.ly/3DAcKKH。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Cystic fibrosis transmembrane conductance regulator therapy with elexacaftor/tezacaftor/ivacaftor reduces detection of hallmark cystic fibrosis pathogens in Europe: progress made but no time to slow down.

查看原文本刊更多论文

ETI reduces pathogen detection rates in respiratory samples, yet a significant proportion of pwCF continue to harbour hallmark pathogens putting them at risk of more rapid decline in lung function https://bit.ly/3DAcKKH.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

ERJ Open Research Medicine-Pulmonary and Respiratory Medicine

CiteScore

6.20

自引率

4.30%

发文量

273

审稿时长

8 weeks

期刊介绍： ERJ Open Research is a fully open access original research journal, published online by the European Respiratory Society. The journal aims to publish high-quality work in all fields of respiratory science and medicine, covering basic science, clinical translational science and clinical medicine. The journal was created to help fulfil the ERS objective to disseminate scientific and educational material to its members and to the medical community, but also to provide researchers with an affordable open access specialty journal in which to publish their work.